Background The clinical manifestations of nonclassical 11beta-hydroxylase deficiency are very similar to those of nonclassical 21-hydroxylase deficiency.For this study,we investigated the relationship between the clin...Background The clinical manifestations of nonclassical 11beta-hydroxylase deficiency are very similar to those of nonclassical 21-hydroxylase deficiency.For this study,we investigated the relationship between the clinical and molecular features of congenital adrenal hyperplasia caused by 11beta-hydroxylase deficiency and reviewed the related literature,which are expected to provide assistance for the clinical diagnosis and analysis of congenital adrenal hyperplasia.Methods Clinical data for 10 Chinese patients diagnosed with congenital adrenal hyperplasia in our hospital from 2018 to 2022 were retrospectively analyzed.We examined the effects of gene mutations on protease activity and constructed threedimensional structure prediction models of proteins.Results We describe 10 patients with 11beta-hydroxylase gene mutations(n=5,46,XY;n=5,46,XX),with 10 novel mutations were reported.Female patients received treatment at an early stage,with an average age of 2.08±1.66 years,whereas male patients received treatment significantly later,at an average age of 9.77±3.62 years.The most common CYP11B1 pathogenic variant in the Chinese population was found to be c.1360C>T.All mutations lead to spatial conformational changes that affect protein stability.Conclusions Our study found that there was no significant correlation between each specific mutation and the severity of clinical manifestations.Different patients with the same gene pathogenic variant may have mild or severe clinical manifestations.The correlation between genotype and phenotype needs further study.Three-dimensional protein simulations may provide additional support for the physiopathological mechanism of genetic mutations.展开更多
目的观察玉屏风散对肺气虚模型大鼠Janus激酶1/信号转导及转录活化因子3(janus kinase 1/signal transducer and activator of transcription 3,JAK1/STAT3)信号通路及其上下游炎性因子的影响,探讨玉屏风散改善肺气虚证的作用机制。方...目的观察玉屏风散对肺气虚模型大鼠Janus激酶1/信号转导及转录活化因子3(janus kinase 1/signal transducer and activator of transcription 3,JAK1/STAT3)信号通路及其上下游炎性因子的影响,探讨玉屏风散改善肺气虚证的作用机制。方法60只Sprague Dawley(SD)大鼠随机分为空白组,模型组,玉屏风散高、中、低剂量组,阳性对照组,每组10只。除空白组外,其余各组大鼠均采用烟熏加脂多糖气管滴入方法建立肺气虚模型,造模开始灌胃给药,玉屏风散高、中、低剂量组分别予玉屏风散汤液[浓度分别为24、12、6 g/(kg·d)],阳性对照组予地塞米松[0.2 mg/(kg/d)],空白组、模型组给予等体积0.9%生理盐水,连续给药30 d。观察治疗前后各组大鼠症状和体征,肺组织形态学,血清中肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-6(interleukin-6,IL-6)、白细胞介素-8(interleukin-8,IL-8)含量和肺组织中JAK1、STAT3、磷酸化信号转导及转录活化因子3(phosphorylation signal transducer and activator of transcription 3,p-STAT3)、基质金属蛋白酶-9(matrix metalloprotein-9,MMP-9)、组织金属蛋白酶抑制剂1(tissue inhibitor of matrix metalloproteinase 1,TIMP1)蛋白水平的变化。结果与空白组比较,模型组大鼠症状、体征和肺组织损伤状态严重,血清细胞因子TNF-α、IL-6、IL-8显著升高(P<0.01);模型组肺组织中JAK1、STAT3、p-STAT3、MMP-9平均光密度值(Integrated Optical Density,IOD)(P<0.01)和蛋白表达显著升高(P<0.01),TIMP1平均光密度值(P<0.01)和蛋白表达显著降低(P<0.01)。药物治疗后,与模型组比较,玉屏风高剂量组和阳性对照组症状、体征和肺组织损伤状态明显减轻,血清中TNF-α、IL-6、IL-8明显降低(P<0.01),肺组织中JAK1、STAT3、p-STAT3、MMP-9平均光密度值(P<0.01或P<0.05)和蛋白表达明显降低(P<0.01或P<0.05),TIMP1平均光密度值(P<0.01)和蛋白表达明显升高(P<0.01);玉屏风中剂量组症状、体征和肺组织损伤状态减轻,血清TNF-α、IL-6、IL-8降低(P<0.01或P<0.05),肺组织中JAK1、STAT3、p-STAT3、MMP-9平均光密度值明显降低(P<0.01),STAT3、MMP-9蛋白表达明显降低(P<0.01),TIMP1平均光密度值(P<0.01)和蛋白表达明显升高(P<0.01);玉屏风低剂量组症状、体征和肺组织损伤状态有所减轻,肺组织中STAT3、p-STAT3、MMP-9平均光密度值降低(P<0.01或P<0.05),STAT3、MMP-9蛋白表达降低(P<0.05),TIMP1平均光密度值(P<0.01)和蛋白表达升高(P<0.01)。总体上玉屏风散高剂量组疗效优于玉屏风散中剂量组和玉屏风散低剂量组,并与阳性对照组疗效持平。结论玉屏风散通过降低TNF-α、IL-6水平来调控JAK1/STAT3的信号转导,从而减少IL-8的产生,纠正MMP-9/TIMP-1平衡状态,达到抑制气道炎症反应和气道重塑的目的,从而改善肺气虚证的症状、体征和肺组织损伤状态。展开更多
Objectives: To investigate the mechanism of Liuwei Dihuang Pill (六味地黄丸, LDP) in treating postmenopausal osteoporosis (PMOP) with Shen (Kidney) yin deficiency. Methods: In this study, 205 cases of PMOP wer...Objectives: To investigate the mechanism of Liuwei Dihuang Pill (六味地黄丸, LDP) in treating postmenopausal osteoporosis (PMOP) with Shen (Kidney) yin deficiency. Methods: In this study, 205 cases of PMOP were divided into the PMOP Shen-yin deficiency group (Group A), PMOP Shen-yang deficiency group (Group B), PMOP without Shen deficiency group (Group C), and control group (Group N). Real-time polymerase chain reaction (RT-PCR) and Western blot techniques were used to observe the effects of LDP treatment on the cardiotrophin-like cytokine factor 1 (CLCF1), ankyrin repeat and SOCS box containing 1 (ASB1), and proldneticin 2 (PROK2) genes and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway. Results: The mRNA (P〈0.05) and protein (P〈0.01) expression levels of the CLCF1 gone in Group A were significantly lower than the corresponding levels in Group N. After LDP treatment for 3 months, the mRNA expression levels of the CLCF1 gone were obviously up-regulated (P〈0.01). After 6-month treatment, the expression levels of CLCF1 mRNA and protein were significantly up-regulated (both P〈0.01), and the average bone density of the top femur had significantly increased (P〈0.05). In vitro, CLCF1 overexpression resulted in a significant increase in the total protein and phosphorylated protein levels of JAK2 and STAT3. Conclusions: The CLCF1 gone is an important gone associated with PMOP Shen-yin deficiency and the therapeutic effects of LDP may be mediated by up-regulation of CLCF1 gone expression and activation of the JAK/STAT signaling pathway.展开更多
The RNA-editing enzyme ADAR1 is essential for the suppression of innate immune activation and pathology caused by aberrant recognition of self-RNA, a role it carries out by disrupting the duplex structure of endogenou...The RNA-editing enzyme ADAR1 is essential for the suppression of innate immune activation and pathology caused by aberrant recognition of self-RNA, a role it carries out by disrupting the duplex structure of endogenous double-stranded RNA species1,2. A point mutation in the sequence encoding the Z-DNA-binding domain (ZBD) of ADAR1 is associated with severe autoinflammatory disease3-5. ZBP1 is the only other ZBD-containing mammalian protein6, and its activation can trigger both cell death and transcriptional responses through the kinases RIPK1 and RIPK3, and the protease caspase 8 (refs. 7-9). Here we show that the pathology caused by alteration of the ZBD of ADAR1 is driven by activation of ZBP1. We found that ablation of ZBP1 fully rescued the overt pathology caused by ADAR1 alteration, without fully reversing the underlying inflammatory program caused by this alteration.展开更多
文摘Background The clinical manifestations of nonclassical 11beta-hydroxylase deficiency are very similar to those of nonclassical 21-hydroxylase deficiency.For this study,we investigated the relationship between the clinical and molecular features of congenital adrenal hyperplasia caused by 11beta-hydroxylase deficiency and reviewed the related literature,which are expected to provide assistance for the clinical diagnosis and analysis of congenital adrenal hyperplasia.Methods Clinical data for 10 Chinese patients diagnosed with congenital adrenal hyperplasia in our hospital from 2018 to 2022 were retrospectively analyzed.We examined the effects of gene mutations on protease activity and constructed threedimensional structure prediction models of proteins.Results We describe 10 patients with 11beta-hydroxylase gene mutations(n=5,46,XY;n=5,46,XX),with 10 novel mutations were reported.Female patients received treatment at an early stage,with an average age of 2.08±1.66 years,whereas male patients received treatment significantly later,at an average age of 9.77±3.62 years.The most common CYP11B1 pathogenic variant in the Chinese population was found to be c.1360C>T.All mutations lead to spatial conformational changes that affect protein stability.Conclusions Our study found that there was no significant correlation between each specific mutation and the severity of clinical manifestations.Different patients with the same gene pathogenic variant may have mild or severe clinical manifestations.The correlation between genotype and phenotype needs further study.Three-dimensional protein simulations may provide additional support for the physiopathological mechanism of genetic mutations.
文摘目的观察玉屏风散对肺气虚模型大鼠Janus激酶1/信号转导及转录活化因子3(janus kinase 1/signal transducer and activator of transcription 3,JAK1/STAT3)信号通路及其上下游炎性因子的影响,探讨玉屏风散改善肺气虚证的作用机制。方法60只Sprague Dawley(SD)大鼠随机分为空白组,模型组,玉屏风散高、中、低剂量组,阳性对照组,每组10只。除空白组外,其余各组大鼠均采用烟熏加脂多糖气管滴入方法建立肺气虚模型,造模开始灌胃给药,玉屏风散高、中、低剂量组分别予玉屏风散汤液[浓度分别为24、12、6 g/(kg·d)],阳性对照组予地塞米松[0.2 mg/(kg/d)],空白组、模型组给予等体积0.9%生理盐水,连续给药30 d。观察治疗前后各组大鼠症状和体征,肺组织形态学,血清中肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-6(interleukin-6,IL-6)、白细胞介素-8(interleukin-8,IL-8)含量和肺组织中JAK1、STAT3、磷酸化信号转导及转录活化因子3(phosphorylation signal transducer and activator of transcription 3,p-STAT3)、基质金属蛋白酶-9(matrix metalloprotein-9,MMP-9)、组织金属蛋白酶抑制剂1(tissue inhibitor of matrix metalloproteinase 1,TIMP1)蛋白水平的变化。结果与空白组比较,模型组大鼠症状、体征和肺组织损伤状态严重,血清细胞因子TNF-α、IL-6、IL-8显著升高(P<0.01);模型组肺组织中JAK1、STAT3、p-STAT3、MMP-9平均光密度值(Integrated Optical Density,IOD)(P<0.01)和蛋白表达显著升高(P<0.01),TIMP1平均光密度值(P<0.01)和蛋白表达显著降低(P<0.01)。药物治疗后,与模型组比较,玉屏风高剂量组和阳性对照组症状、体征和肺组织损伤状态明显减轻,血清中TNF-α、IL-6、IL-8明显降低(P<0.01),肺组织中JAK1、STAT3、p-STAT3、MMP-9平均光密度值(P<0.01或P<0.05)和蛋白表达明显降低(P<0.01或P<0.05),TIMP1平均光密度值(P<0.01)和蛋白表达明显升高(P<0.01);玉屏风中剂量组症状、体征和肺组织损伤状态减轻,血清TNF-α、IL-6、IL-8降低(P<0.01或P<0.05),肺组织中JAK1、STAT3、p-STAT3、MMP-9平均光密度值明显降低(P<0.01),STAT3、MMP-9蛋白表达明显降低(P<0.01),TIMP1平均光密度值(P<0.01)和蛋白表达明显升高(P<0.01);玉屏风低剂量组症状、体征和肺组织损伤状态有所减轻,肺组织中STAT3、p-STAT3、MMP-9平均光密度值降低(P<0.01或P<0.05),STAT3、MMP-9蛋白表达降低(P<0.05),TIMP1平均光密度值(P<0.01)和蛋白表达升高(P<0.01)。总体上玉屏风散高剂量组疗效优于玉屏风散中剂量组和玉屏风散低剂量组,并与阳性对照组疗效持平。结论玉屏风散通过降低TNF-α、IL-6水平来调控JAK1/STAT3的信号转导,从而减少IL-8的产生,纠正MMP-9/TIMP-1平衡状态,达到抑制气道炎症反应和气道重塑的目的,从而改善肺气虚证的症状、体征和肺组织损伤状态。
基金Supported by National Natural Science Foundation of China(Nos.81173280,81302995,81403420)Fujian Medical Innovation project(No.2011-CX-30)+1 种基金Science and Technology Department of Fujian Province autonomous non-profit research institutes topics project(No.2011R1038-5)Fujian Academy of Traditional Chinese autonomous topics Project(No.2012fjzyyk-5)
文摘Objectives: To investigate the mechanism of Liuwei Dihuang Pill (六味地黄丸, LDP) in treating postmenopausal osteoporosis (PMOP) with Shen (Kidney) yin deficiency. Methods: In this study, 205 cases of PMOP were divided into the PMOP Shen-yin deficiency group (Group A), PMOP Shen-yang deficiency group (Group B), PMOP without Shen deficiency group (Group C), and control group (Group N). Real-time polymerase chain reaction (RT-PCR) and Western blot techniques were used to observe the effects of LDP treatment on the cardiotrophin-like cytokine factor 1 (CLCF1), ankyrin repeat and SOCS box containing 1 (ASB1), and proldneticin 2 (PROK2) genes and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway. Results: The mRNA (P〈0.05) and protein (P〈0.01) expression levels of the CLCF1 gone in Group A were significantly lower than the corresponding levels in Group N. After LDP treatment for 3 months, the mRNA expression levels of the CLCF1 gone were obviously up-regulated (P〈0.01). After 6-month treatment, the expression levels of CLCF1 mRNA and protein were significantly up-regulated (both P〈0.01), and the average bone density of the top femur had significantly increased (P〈0.05). In vitro, CLCF1 overexpression resulted in a significant increase in the total protein and phosphorylated protein levels of JAK2 and STAT3. Conclusions: The CLCF1 gone is an important gone associated with PMOP Shen-yin deficiency and the therapeutic effects of LDP may be mediated by up-regulation of CLCF1 gone expression and activation of the JAK/STAT signaling pathway.
文摘The RNA-editing enzyme ADAR1 is essential for the suppression of innate immune activation and pathology caused by aberrant recognition of self-RNA, a role it carries out by disrupting the duplex structure of endogenous double-stranded RNA species1,2. A point mutation in the sequence encoding the Z-DNA-binding domain (ZBD) of ADAR1 is associated with severe autoinflammatory disease3-5. ZBP1 is the only other ZBD-containing mammalian protein6, and its activation can trigger both cell death and transcriptional responses through the kinases RIPK1 and RIPK3, and the protease caspase 8 (refs. 7-9). Here we show that the pathology caused by alteration of the ZBD of ADAR1 is driven by activation of ZBP1. We found that ablation of ZBP1 fully rescued the overt pathology caused by ADAR1 alteration, without fully reversing the underlying inflammatory program caused by this alteration.